Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 29.6% and free cash flow fell 125.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TENX
Tenax Therapeutics, Inc. (TENX) EV/Sales
As of 16 October 2026, Tenax Therapeutics, Inc. (TENX) trades at a EV/Sales of −142×. Over the past ten years it has ranged from −142× (October 2026) to 2,366× (July 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 157× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2015 | 259× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. | −142× |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | 0.6× |
| GOSS Gossamer Bio, Inc. compare | 4.0× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 8.6× |
| GANX Gain Therapeutics, Inc. compare | 211× |
| GUTS Fractyl Health, Inc. compare | 2,465× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)